ProQR R&D day

ProQR will organize its second R&D Day on June 15, 2017 in New York, NY.

The R&D Day will feature presentations by ProQR management on the progress on its pipeline, including a review and introduction of several near- and medium term value drivers. In addition, several key opinion leaders will discuss the state of the art in research and development on critical areas of the company’s pipeline including CF, inherited blindness, debilitating skin diseases and RNA technologies.

Summary of discussed topics during R&D Day
  • Presentations on development programs: QR-010 for cystic fibrosis, QR-110 for Leber’s congenital amaurosis Type 10 (LCA 10) and QR-313 for dystrophic epidermolysis bullosa (DEB)
  • An update on the Ophthalmology pipeline including programs for Usher syndrome and the Dermatorlogy pipeline including other DEB mutations
  • An introduction to ProQR’s novel RNA editing platform technology called Axiomer
Presentations from the speakers will start at 8:00 AM and last until 12:00 PM EST.

Kindly RSVP to Ronen Abergel at to reserve a seat or for additional information.

ProQR R&D day will be live webcasted, please register using the button below. The webcast is archived on our website for 90 days.

ProQR R&D Day webcast

Register and watch here

Program / timetable
ProQR speakers
  • Daniel de Boer - Chief Executive Officer
  • Noreen Henig, M.D. - Chief Medical Officer
  • Peter Adamson, Ph.D. - Head of Ophthalmology Research
  • Gerard Platenburg - Chief Innovation Officer
  • Dave Rodman - Chief Development Strategy Officer
Key Opinion Leader speakers
  • Stephen Rose, Ph.D. - Chief Research Officer at Foundation Fighting Blindness
  • Art Levin, Ph.D. - Executive Vice President, Research and Development at Avidity Biosciences
  • Steven M. Rowe, M.D., MSPH. - Professor, Department of Medicine, Pediatrics and Cell Developmental & Integrative Biology; Director, Gregory Fleming James Cystic Fibrosis Research Center University of Alabama
  • M. Peter Marinkovich, M.D. - Associate Professor, Blistering Disease Clinic Department of Dermatology at Stanford University School of Medicine

You are now leaving ProQR Therapeutics

ProQR Therapeutics provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained by ProQR Therapeutics, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.

You will be redirected to

Click the link above to continue or CANCEL